相关实验视频
Updated: Mar 14, 2026

06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
1.9K
早期治疗反应预测慢性便秘的结果:一个多中心前性观察研究.
Tadayuki Oshima1,2,3, Seiji Futagami4,3, Yoshimasa Tanaka5,3
1Department of Gastroenterology and Hepatology, Hyogo Medical University, Nishinomiya, Japan.
Gastroenterology research
|March 13, 2026
概括
慢性便秘的早期治疗反应是关键. 在两周内没有反应的患者可能会在四周内出现较差的治疗结果,这凸显了早期有效性评估的重要性.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 慢性便秘会影响生活质量,在临床实践中很常见.
- 治疗慢性便秘疗效的预测因素尚不清楚.
- 识别这些预测因素对于优化患者护理至关重要.
研究的目的:
- 确定预测慢性便秘患者成功治疗结果的因素.
- 为了确定早期治疗反应是否可以预测长期疗效.
主要方法:
- 进行了一项多中心的前性观察性研究.
- 患有慢性便秘 (中度至重度) 的患者使用CC-TEST问卷进行了评估.
- 多变量分析确定了基于患者印象,症状强度 (NRS) 和治疗后2周和4周自发排便 (SBM) 频率的预测因素.
主要成果:
- 97名患者接受了便秘药物治疗,在2周和4周后症状明显改善.
- 2周的早期治疗反应,特别是不反应,是NRS和SBM患者印象和结果较差的重要预测因素.
- 结合2周的不响应改善了4周治疗疗效的预测准确度.
结论:
- 在两周观察到的治疗反应是随后在四周治疗反应的最重要的预测因素.
- 早期评估慢性便秘治疗的疗效对于预测长期结果至关重要.
- 这一发现可以帮助临床医生更有效地定制治疗策略.
更多相关视频
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
Drugs for Treatment of Diarrhea-Predominant IBS
832
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
832
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
Chronic Bowel Disorders: Introduction
871
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
871
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.2K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
998
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
998

